Hospital
Arh Mary Breckinridge Health Services, INC.
Arh Mary Breckinridge Health Services, INC. was paid $16.24M by Medicaid between Jan 2018 and Dec 2024, across 137 billing codes. Its largest line is 99284, emergency room visit (serious) — 26% of everything it billed.
33Billing provider infoARH MARY BRECKINRIDGE HEALTH SERVICES, INC.
HYDEN, KY 41749
HYDEN, KY 41749
33aNPI1649554007assigned 10/04/2011
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$16.24M
24GClaims314,456
24DCodes billed137
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,234 | $2.23M | |
| 2019 | 45,083 | $2.41M | |
| 2020 | 43,038 | $1.94M | |
| 2021 | 51,916 | $2.40M | |
| 2022 | 44,306 | $2.24M | |
| 2023 | 40,958 | $2.55M | |
| 2024incomplete | 35,921 | $2.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 9,751 | 7,412 | $4.30M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 9.5% | 2,170 | 1,867 | $1.54M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 2,931 | 1,837 | $1.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.9% | 9,298 | 8,029 | $1.12M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 1,435 | 1,229 | $539K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.2% | 6,222 | 1,768 | $520K |
| 36415 | Collection of venous blood by venipuncture | 3.2% | 80,986 | 22,731 | $512K |
| 80053 | Comprehensive metabolic panel | 2.9% | 21,600 | 14,196 | $478K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 5,761 | 4,220 | $279K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 5,007 | 1,865 | $277K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 3,910 | 3,553 | $268K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 21,351 | 16,506 | $261K |
125 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 5,791 | $241K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 2,745 | $230K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 3,800 | $217K |
| 87631 | 1.3% | 1,937 | $205K | |
| 71045 | Radiologic examination, chest; single view | 1.2% | 4,304 | $199K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 6,315 | $183K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.1% | 253 | $172K |
| 84484 | 1.0% | 4,674 | $168K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,621 | $151K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,490 | $137K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,579 | $129K |
| 80061 | Lipid panel | <1% | 5,085 | $129K |
| 87040 | <1% | 1,929 | $120K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,687 | $119K |
| G0378 | Hospital observation service, per hour | <1% | 260 | $118K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,794 | $114K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,245 | $112K |
| 83735 | <1% | 4,490 | $111K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,024 | $105K |
| 83690 | <1% | 2,890 | $99K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,633 | $93K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,074 | $92K |
| 82150 | <1% | 1,425 | $90K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 648 | $82K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,545 | $80K |
| 83880 | <1% | 1,929 | $75K | |
| 82607 | <1% | 3,570 | $74K | |
| 81001 | <1% | 7,309 | $70K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,018 | $65K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,856 | $53K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,001 | $53K |
| 83605 | <1% | 1,245 | $52K | |
| 72100 | <1% | 728 | $44K | |
| 93041 | <1% | 1,962 | $42K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,163 | $41K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,045 | $41K |
| 81025 | <1% | 1,046 | $36K | |
| 87070 | <1% | 1,439 | $34K | |
| 87186 | <1% | 1,304 | $32K | |
| 84703 | <1% | 1,247 | $32K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 26 | $32K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 143 | $30K |
| 85730 | <1% | 608 | $26K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 350 | $24K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 191 | $22K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 59 | $20K |
| 85610 | <1% | 1,351 | $20K | |
| 97162 | <1% | 340 | $18K | |
| 74018 | <1% | 260 | $18K | |
| 84145 | <1% | 205 | $17K | |
| 73610 | <1% | 192 | $15K | |
| 73030 | <1% | 265 | $15K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 42 | $15K |
| 73630 | <1% | 211 | $14K | |
| 82553 | <1% | 563 | $14K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 177 | $13K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 435 | $13K |
| 80074 | <1% | 216 | $13K | |
| 87076 | <1% | 1,227 | $13K | |
| 82550 | <1% | 956 | $12K | |
| 87077 | <1% | 1,277 | $12K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $12K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 679 | $12K |
| 96376 | <1% | 321 | $11K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 162 | $10K |
| 73130 | <1% | 149 | $10K | |
| 84439 | <1% | 615 | $10K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,077 | $10K |
| 74022 | <1% | 43 | $9K | |
| 82728 | <1% | 362 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 186 | $8K |
| 0002A | <1% | 522 | $8K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 601 | $7K |
| 87581 | <1% | 143 | $7K | |
| 85652 | <1% | 1,046 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 162 | $7K |
| 87486 | <1% | 143 | $7K | |
| 0001A | <1% | 621 | $6K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 116 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,647 | $5K |
| 73562 | <1% | 75 | $5K | |
| 81002 | <1% | 587 | $5K | |
| 87522 | Neg quan hep c or qual rna | <1% | 100 | $5K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 113 | $4K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 23 | $4K |
| 0100U | <1% | 64 | $4K | |
| 83970 | <1% | 62 | $4K | |
| 82803 | <1% | 62 | $4K | |
| 83540 | <1% | 302 | $4K | |
| 84550 | <1% | 514 | $3K | |
| 82746 | <1% | 120 | $3K | |
| 83550 | <1% | 197 | $3K | |
| 82043 | <1% | 286 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 304 | $2K |
| 36600 | <1% | 83 | $2K | |
| 72040 | <1% | 43 | $2K | |
| 87449 | <1% | 40 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 44 | $2K |
| 87634 | <1% | 28 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 482 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 283 | $1K |
| 97166 | <1% | 14 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 310 | $1K |
| 82570 | <1% | 87 | $978.63 | |
| 80305 | <1% | 54 | $846.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 56 | $796.06 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 315 | $725.36 |
| 0011A | <1% | 51 | $566.77 | |
| 86038 | <1% | 28 | $540.92 | |
| 85378 | <1% | 35 | $534.70 | |
| 73110 | <1% | 15 | $534.54 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 43 | $499.09 |
| 84100 | <1% | 51 | $497.55 | |
| 0012A | <1% | 36 | $456.92 | |
| 84481 | <1% | 17 | $265.58 | |
| 86703 | <1% | 22 | $246.08 | |
| 36416 | <1% | 47 | $202.62 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 14 | $201.61 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 118 | $153.73 |
| 86200 | <1% | 14 | $153.13 | |
| 80076 | <1% | 15 | $126.62 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 17 | $22.18 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 14 | $4.67 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 29 | $2.56 |
| A9270 | Non-covered item or service | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Parent organizationAPPALACHIAN REGIONAL HELATHCARE, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.